LONDON, Nov. 2, 2016 /PRNewswire/ -- This Persistence Market Research (PMR) report examines the global diabetic gastroparesis treatment market and identifies trends likely to govern the market during the period 2016-2024. The primary objective of the report is to offer updates and information related to market opportunities in the global diabetic gastroparesis treatment market. The report analyzes the global diabetic gastroparesis treatment market in terms of market value. This report also provides useful information on drugs and surgical treatment products used for patients suffering from diabetic gastroparesis disorder. To understand and assess opportunities in this market, the report is categorically split into four sections based on product type, disease indication, distribution channel, and region. The report starts with an overview of the global diabetic gastroparesis treatment market along with product categories used to control the symptoms of diabetic gastroparesis disorder such as nausea, vomiting, and abdominal pain. This section also covers the revenue performance of the diabetic gastroparesis treatment market both globally as well as regionally. A detailed analysis of key trends, drivers, and restraints from the supply and demand perspectives are also included. The next few sections analyze the market based on product type, disease indication, distribution channel, and region and present a forecast in terms of value for the period 2016 to 2024.In the final section of the report, the global diabetic gastroparesis treatment market landscape is included to provide report audiences with a dashboard view based on categories of providers in the global diabetic gastroparesis treatment product portfolio. The report provides insights into key developments and strategies adopted by leading companies operating in this market. Some of the market leaders profiled in the report include Janssen Global Services, LLC, Salix Pharmaceuticals, Inc., Abbott Laboratories, Medtronic, C. R. Bard, Inc., Kimberly-Clark Corporation, Boston Scientific Corporation, Cardinal Health, Inc., Rhythm Pharmaceuticals, Inc., Evoke Pharma, and Alfa Wassermann SPA.